Biography

Download Curriculum Vitae

Dr. Mack C. Mitchell is Vice President for Medical Affairs at UT Southwestern Medical Center and the Nancy S. and Jeremy L. Professor of Gastroenterology. Before joining the faculty at UT Southwestern in 2011, he was Director of Gastroenterology at Johns Hopkins Bayview Medical Center and Chairman of Internal Medicine at Carolinas Medical Center. Dr. Mitchell received his M.D. from Johns Hopkins School of Medicine where he was elected to Alpha Omega Alpha before completing residency in internal medicine at the Johns Hopkins Hospital and fellowship in gastroenterology and clinical pharmacology at Vanderbilt University. He is a fellow of the American College of Physicians and the American Association for the Study of Liver Diseases.

Dr. Mitchell previously served as Chair of the Board of Scientific Councilors of the National Institute of Alcohol Abuse and Alcoholism and on the Advisory Council of the National Institute for Alcohol Abuse and Alcoholism, the examination committee of the American Board of Internal Medicine, the research committee of AASLD and ABMRF, the Foundation for Alcohol Research. He is principal investigator for an NIH sponsored clinical research study on liver disease related to alcohol and has authored or co-authored numerous papers and chapters on alcohol and liver diseases.

Education

Medical School
Johns Hopkins University School of Medicine (1977)
Residency
Johns Hopkins Hospital (1979), Internal Medicine
Fellowship
Johns Hopkins Hospital (1980), Hepatology
Fellowship
Vanderbilt University School of Medicine (1982), Gastroenterology

Research Interest

  • Alcohol-associated hepatitis
  • Alcohol-associated liver disease

Publications

Featured Publications LegendFeatured Publications

The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes.
Cotter TG, Odenwald MA, Lieber SR, Rich NE, Im G, Charlton M, Singal AG, Mitchell MC, Transplant Direct 2022 Mar 8 3 e1297
IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
Szabo G, Mitchell M, McClain CJ, Dasarathy S, Barton B, McCullough AJ, Nagy LE, Kroll-Desrosiers A, Tornai D, Min HA, Radaeva S, Holbein MEB, Casey L, Cuthbert J, Hepatology 2022 Mar
Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population.
Lazo M, Bilal U, Mitchell MC, Potter J, Hernaez R, Clark JM, Clin Gastroenterol Hepatol 2020 Aug
Keratin 18 Is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis.
Vatsalya V, Cave MC, Kong M, Gobejishvili L, Falkner KC, Craycroft J, Mitchell M, Szabo G, McCullough A, Dasarathy S, Radaeva S, Barton B, McClain CJ, Clin. Gastroenterol. Hepatol. 2020 Aug 18 9 2046-2054
Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.
Dasarathy S, Mitchell MC, Barton B, McClain CJ, Szabo G, Nagy LE, Radaeva S, McCullough AJ, Contemp Clin Trials 2020 Jul 96 106094
Diagnostic and Prognostic Significance of Complement in Patients with Alcohol-associated Hepatitis.
Fan X, McCullough RL, Huang E, Bellar A, Kim A, Poulsen KL, McClain CJ, Mitchell M, McCullough AJ, Radaeva S, Barton B, Szabo G, Dasarathy S, Rotroff DM, Nagy LE, Hepatology 2020 Jun
Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.
Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, Mitchell M, McCullough A, Dasarathy S, Kroll-Desrosiers A, Barton B, Radaeva S, Szabo G, Hepatology 2019 10 70 4 1134-1149
Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease.
Jia L, Chang X, Qian S, Liu C, Lord CC, Ahmed N, Lee CE, Lee S, Gautron L, Mitchell MC, Horton JD, Scherer PE, Elmquist JK Mol Metab 2018 May
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G Gastroenterology 2016 Feb
Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis.
Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, Veech RL Alcohol. Clin. Exp. Res. 1990 Apr 14 2

Honors & Awards

  • Research Society on Alcoholism
    Seixas Award for Distinguished Service (2007)

Professional Associations/Affiliations

  • American Association for the Study of Liver Diseases
  • American College of Physicians
  • Research Society on Alcoholism